Traditional anticoagulant therapy: Why abandon half a century of success?

American Journal of Health-System Pharmacy

Volumn 59, Issue SUPPL. 6, 2002, Pages

  Bussey, Henry ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Anticoagulants; Dosage schedules; Drugs, availability; Half life; Heparin; Heparins; International normalized ratio; Pharmacodynamics; Pharmacokinetics; Thromboembolism; Toxicity; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULATION; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; HIP FRACTURE; HUMAN; PRIORITY JOURNAL; REBOUND; RECURRENCE RISK; THROMBOCYTOPENIA; THROMBOEMBOLISM; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT;

EID: 0037109007     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/59.suppl_6.s3     Document Type: Conference Paper

References (19)

1. Sixth Consensus Conference on Antithrombotic Therapy. Chest. 2001; 119 (suppl 1):1S-370S.
2. Kearon C, Gent M, Hirsh J et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous'thromboembolism. N Engl J Med. 1999; 340:901-7.
3. Agnelli G, Prandoni P, Santamaria MG et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med. 2001; 345:165-9.
4. Albers GW, Sherman DG, Gress DR et al. Stroke prevention in nonvalvular atrial fibrillation: a review of prospective randomized trials. Ann Neurol. 1991; 30:511-8.
5. Geerts WH, Heit JA, Clagett P et al. Prevention of venous thromboembolism. Chest. 2001; 119(suppl 1):132S-76S.
6. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. N Engl J Med. 2000; 342:1953-8.
7. Hirsh J, Dalen JE, Anderson DR et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001; 119(suppl 1):64S-94S.
8. Kearon C, Johnston M, Moffat K et al. Effect of warfarin on activated partial thromboplastin time in patients receiving heparin. Arch Intern Med. 1998; 158:1140-3.
9. Baker BA, Adelman MD, Smith PA et al. Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays. Arch Intern Med. 1997; 157:2475-9.
10. Warkentin TE, Levine MN, Hirsh J et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparins or unfractionated heparin. N Engl J Med. 1995; 332:1330-5.
11. Palareti G, Legnani C, Guazzaloca G et al. Activation of blood coagulation after abrupt or stepwise withdrawal of oral anticoagulants - a prospective study. Thromb Haemost. 1994; 72:222-6.
12. Ansell J, Hirsh J, Dalen J et al. Managing oral anticoagulant therapy. Chest. 2001(suppl 1); 119:22S-38S.
13. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic and usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med. 1998; 158:1641-7.
14. Cortelazzo S, Finazzi G, Viero P et al. Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. Thromb Haemost. 1993; 69:316-20.
15. Garabedian-Ruffalo SM, Gray DR, Sax MJ et al. Retrospective evaluation of a pharmacist-managed warfarin anticoagulation clinic. Am J Hosp Pharm. 1985; 42:304-8.
16. Wilt VM, Gums JG, Ahmed OI et al. Outcome analysis of a pharmacist-managed anticoagulation service. Pharmacotherapy. 1995; 15:732-9.
17. McIntyre K. Medicolegal implication of the consensus conference. Chest. 2001; 119(suppl 1):337S-43S.
18. Hyers TM, Agnelli G, Hull RD et al. Antithrombotic therapy for venous thromboembolic disease. Chest. 2001; 119(suppl 1):176S-93S.
19. Hull RD, Pineo GF, Mah AF et al. Home-life: safety and efficacy results for a study investigating the long-term out-of-hospital treatment of patients with proximal venous thrombosis using subcutaneous low-molecular-weight heparin versus warfarin. Paper presented at the XVIII Congress of the International Society of Thrombosis and Haemostasis. Paris, France; 2001 Jul 6-12.